Trials / Completed
CompletedNCT00684944
Open Label Study of TRx0014 in Alzheimer's Disease
An Open Label Continuation Study of the Effects of TRx0014 30 mg TID and 60 mg TID in Patients With Alzheimer's Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 111 (actual)
- Sponsor
- TauRx Therapeutics Ltd · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This is an open label, dose-ranging study of two doses of TRx0014 in patients with mild or moderate Alzheimer's Disease. The trial is made available to any patient ongoing on treatment in the clinical trial designated TRx-014-001 at termination of that study. Treatment for each individual patient will continue for as long as the treating physician feels there is benefit to the patient. This current protocol covers each patient for 12 months in the first instance.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TRx0014 | Gelatin capsule, tid |
Timeline
- Start date
- 2007-09-13
- Primary completion
- 2010-12-02
- Completion
- 2010-12-02
- First posted
- 2008-05-28
- Last updated
- 2018-04-27
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT00684944. Inclusion in this directory is not an endorsement.